Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients
- Conditions
- obese type 2 diabetic hemodialysis patientsTherapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Registration Number
- EUCTR2020-000043-31-FR
- Lead Sponsor
- Groupe Hospitalier Paris Saint-Joseph
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 30
- Patient aged = 18 and <70
- Patient on hemodialysis for more than 6 months
- Type 2 diabetic patient
- Patient with a BMI> 30 kg / m2 with a Temporary Contraindication for kidney transplant for renal transplant due to overweight by his graft center
- Patient affiliated to a health insurance plan
- French speaking patient
- Patient having given free, informed and written consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20
- Patient with a Temporary Contraindication for kidney transplant for a cause other than overweight
- Patient with personal or family history of thyroid medullary cancer
- Patient with a history of acute or chronic pancreatitis
- Patient who has already had hypersensitivity to liraglutide (or to any other component of the product)
- Patient who has already had a severe digestive intolerance to taking GLP-1 receptor agonists (such as exenatide or lixisenatide)
- Patient already included in an interventional risk research protocol (RIPH1)
- Pregnant or lactating woman
- Patient under guardianship or curatorship
- Patient deprived of liberty
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method